Clostridium difficile infection (CDI) is a growing nosocomial and public health problem.
pseudomembranous colitis, recommendations

Full Text
Clostridium difficile infection (CDI) is a growing nosocomial and public health problem with mortality up to 25% in frail elderly people. CDI may present as fulminant colitis in approximately 3% of patients and account for most of the serious complications including perforation, prolonged ileus, megacolon and death. Accurate diagnosis of CDI is essential for optimal treatment and prevention but continues to be challenging.
(i)
Clinical diagnosis: Clinically, the disease can be diagnosed by symptoms of explosive watery, green, foul-smelling or bloody diarrhea accompanied by abdominal cramps, leukocytosis, fever, nausea, anorexia, malaise, dehydration and delirium. Clinical suspicion for CDI is important because stool assays for diagnosing CDI are not widely available.
(ii) Endoscopic diagnosis: By inserting a flexible endoscope with a camera, the colon can be examined. Pseudomembranous colitis (PMC) when present appears as multiple yellow-white friable plaques, a few centimeters in size, attached to the underlying mucosa. Delay in the diagnosis of PMC could be lethal due to development of toxic megacolon (>7 cm diameter) accompanied by severe systemic toxicity or perforation. Endoscopy should be avoided in patients with paralytic ileus or colonic dilatation because of the risk of perforation. It is better reserved for special situations, such as when the patient is seriously ill and the results of rapid but not highly sensitive non-invasive tests are negative or delayed and CDI is strongly suspected.
(iii) Computed tomographic scan/abdominal x-rays: PMC can sometimes be diagnosed by computed tomographic (CT) scan when diarrhea is absent but abdominal pain, fever and leukocytosis occur. CT scan findings are most useful in PMC cases localized to the proximal colon and may reveal colonic distension, thickening, pericolonic inflammation, or free air.
Abdominal plain films may also demonstrate small bowel dilatation, air-fluid levels and scalloping of the bowel wall due to submucosal edema In 2009, nucleic acid amplification tests (NAATs) based on the detection of toxin genes became commercially available for the diagnosis of CDI. These methods have been compared to toxigenic culture and showed a good correlation. Results can be provided to clinicians within the same day. According to the different assays, the tests are amenable to both batch and on-demand testing. The cost of these assays is still prohibitive for many laboratories and their place among the different diagnostic options remains to be clarified.
Recommendations
The best standard laboratory test for diagnosis has not been clearly established for the past 30 years. There are currently two reference assays for the diagnosis of CDI with different targets: the cytotoxicity assay that detects free toxins and the toxigenic culture which detects the organism with the potential to produce toxin. a) NAAT for C. difficile toxin genes such as PCR are superior to toxins A+B enzyme immunoassay testing as a standard diagnostic test for CDI.
b) GDH screening tests for C difficile can be used with subsequent toxin A and B enzyme immunoassay testing but the sensitivity is lower than NAATs. c) Only stools from patients with diarrhea should be tested for C. difficile.
d) Repeat testing should be discouraged.
e) Testing for cure should not be done.
